Aquatic Capital Management LLC Buys 61,927 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Aquatic Capital Management LLC raised its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 52.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 180,927 shares of the company's stock after acquiring an additional 61,927 shares during the quarter. Aquatic Capital Management LLC's holdings in Takeda Pharmaceutical were worth $2,395,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc bought a new stake in Takeda Pharmaceutical during the 4th quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical during the third quarter worth $40,000. Farther Finance Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in shares of Takeda Pharmaceutical in the fourth quarter valued at about $52,000. Finally, Cromwell Holdings LLC acquired a new position in Takeda Pharmaceutical during the 4th quarter worth about $61,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Trading Up 1.9 %

TAK traded up $0.29 during midday trading on Friday, reaching $15.32. 1,387,023 shares of the company were exchanged, compared to its average volume of 1,874,752. The stock has a market capitalization of $48.75 billion, a P/E ratio of 38.30, a PEG ratio of 0.24 and a beta of 0.26. The stock's 50-day simple moving average is $14.84 and its 200 day simple moving average is $13.97. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.39.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.